Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.

Abstract: A kit for resuscitating a subject, particularly a neonatal patient, is described. In an embodiment, the kit includes a syringe having a tip defining a male Luer taper fitting, and an adaptor defining a first end portion shaped to couple with the male Luer taper fitting and a second end portion shaped to cooperatively couple with an opening of an endotracheal tube.

Abstract: In general, the present invention is directed to systems and methods of utilizing an application operating on a mobile device to determine any applicable offers or eligibility and rank such offers and eligibility for user selection. More specifically, a process may be conducted by a processor in communication with a mobile device and data stores including user data, retailer data, and/or product and service data, the process including comparing identification information associated with a product or service received from the mobile device with data in the data stores; determining the product or service and identifying any associated promotional offers or plan eligibility associated with the product or service, the user, and/or the retailer; ranking any promotional offers or plan eligibility based at least in part on size of promotion; transmitting to the mobile device an identifier of applicable promotional offers or plan eligibility.

Abstract: The present invention relates to an apparatus, system and method for delivery of bone graft material in a patient's spine. The graft delivery device according to various embodiments delivers and disperses biologic material to a disc space and without withdrawal from the surgical site. In various embodiments, the graft delivery device includes an elongate hollow tube configured to receive bone graft material, a plunger adapted to extend in the elongate hollow tube and urge the bone graft material through the elongate hollow tube, and an injection device (such as a syringe) configured to contain the bone graft material therein and to connect to an open proximal end of the elongate hollow tube, to discharge the bone graft material from the first injection device into the elongate hollow tube.

Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

Abstract: An example includes a field-flow fractionation device for the continuous separation of sample components including a channel comprising a sample inlet and a plurality of sample outlets, the channel being for coupling to a flow generator for translocating the sample components along the channel in a first direction from the sample inlet to the plurality of sample outlets, an actuator, which is not the flow generator, coupled to the channel, for translocating the sample components in a second direction, at a first angle with the first direction, an array of electrodes for connection to an AC power source, being in a path taken by the sample components in the channel, arranged in a plurality of rows, and in such a way that adjacent rows can be set at different potentials and every other row can be set at the same potential.

Abstract: The invention relates to a particular cosmetic active substance that is constituted through bioconversion by Lactobacillus arizonensis of its original substrate, Simmondisia chinens. The invention also relates to a preparation method, to compositions comprising same, and to uses thereof for cosmetic applications.

Abstract: In one embodiment, a generation facility for producing electricity includes one or more electricity generating elements for producing electricity from a renewable energy source. The generation facility also includes a controller conductively coupled to: (1) a first conductive path leading from the one or more electricity generating elements; (2) a second conductive path leading to a public utility network; and (3) a third conductive path leading to an energy storage system for storing electrical energy. The energy storage system is also conductively coupled to a fourth conductive path leading to the public utility network. The controller includes one or more processors coupled to a non-transitory computer readable storage media embodying software that is operable when executed by the processors to determine whether to send electricity generated by the one or more electricity generating elements to the energy storage system.

Abstract: The present disclosure relates to a system and method for controlling the pressurization of a support structure for handling of a person, the support structure comprising: a body comprising a row of at least two elongated sections adapted to be pressurized; a carrier plate, wherein, in a pressurized loaded condition of one or more of the elongated sections, the carrier plate is adapted to form an at least partially concavely curved front surface; a power unit adapted to pressurize one or more parts of the support structure individually via a respective valve; one or more sensors adapted to measure movements of the person and/or variations or deviations in pressurized parts of the support structure; and a controller configured to control the power unit to pressurize each part of the support structure that is adapted to be pressurized individually, based at least on sensor measurement data from the one or more sensors.

Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Abstract: The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.

Abstract: The invention relates to a gemstone cut, comprising a crown having a flat table and main crown facets (10-12) being arranged around the table (1) and being inclined relative to the table, a girdle (5) at which the gemstone has its largest transverse dimension, and a pavilion adjoining the girdle from below the girdle and having main pavilion facets (7) around the girdle, whereby the number of the main pavilion facets is odd. The invention also relates to an article comprising a gemstone according to the invention and a method for improving the optical properties of a gemstone.

Abstract: Provided herein are several monoclonal antibodies that activate the adhesion activity of human and mouse E-cadherin, including the amino acid sequences for the CDRs that define the binding domains of each monoclonal antibody. Also described are methods of making these antibodies, as well as biologically functional fragments and derivatives thereof; and methods of using them in the treatment, prevention, and/or amelioration of disease and conditions characterized by disruption of normal cell adhesion and/or cell junctions. Specifically contemplated are methods and compositions for the treatment of cancer metastasis as well as inflammatory conditions (such as inflammatory bowel disease and airway inflammation).

Abstract: A continuous patient engagement oral care model configured to boost patient trust and loyalty which will lead to stronger relationships between patients and oral care providers and more consistent visits from the patients. A Cloud-based system and method implemented for such a continuous patient engagement oral care model may be configured to identify treatments that are important to particular patients, propose treatment for consideration or investigation, and solicit feedback on relevance and priority of the proposed treatment plans.

Abstract: An underwater case contains a device for use in wet and dry conditions, such as underwater, extreme hot or cold conditions, or the like. The underwater case includes one or more waterproof seals to keep a contained device safe. The case includes a controller including a non-volatile memory and processor, a radio module configured to provide a short-range wireless connection between the controller and the device and an integrated connection module configured to activate the device. The case includes an input component connected to the controller and configured to receive one or more inputs from a user and transmit, via the short-range wireless connection, instructions to the device based on the one or more inputs.

Abstract: Medical care is facilitated by providing a cognitive engine to compile electronic medical data records of a patient related to a medical condition into an electronic case abstraction. A processor(s) scans a set of electronic files for electronic medical data records of an individual related to a medical condition, where the scanning identifies electronic records which include different file types with different unique identifiers, and which are from different electronic medical records systems. The processor(s) further electronically compiles the identified electronic medical data records of the individual related to the medical condition into the electronic case abstraction, including associating a common case identifier with the identified electronic medical data records of the individual related to the medical condition. Further, the processor(s) electronically provides for display on a display screen in a consolidated view, the electronic case abstraction to facilitate medical care of the individual.

Abstract: A system and method for wireless audio data system configuration is disclosed and described herein.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.